PrLZ regulates EMT and invasion in prostate cancer via the TGF‐β1/p‐smad2/miR‐200 family/ZEB1 axis

Author:

Xie Hongjun1,Chen Jiaqi1,Ma Zhenkun1,Gao Yang1,Zeng Jin1,Chen Yule1,Yang Zhao1,Xu Shan1ORCID

Affiliation:

1. Department of Urology, The First Affiliated Hospital Xi'an Jiaotong University Xi'an China

Abstract

AbstractBackgroundProstate leucine zipper (PrLZ) is a prostate‐specific protein, and our previous study demonstrated that PrLZ enhances the malignant progression of prostate cancer (Pca). However, the roles of PrLZ in epithelial to mesenchymal transition (EMT) remain unknown.MethodsQuantitative real‐time PCR (qRT‐PCR), immunohistochemical (IHC) staining, hematoxylin‐eosin (HE) staining, and western blotting were used to analyze the expression of protein and genes level in human PCa cell lines. Invasion assay was used to examine the effect of PrLZ, miR‐200a, miR‐200b, miR‐200c, miR‐141, miR‐429, miR‐205, and ZEB1 on PCa cell line invasion in vitro. Prostate cancer metastasis animal model was designed to assess the effect of PrLZ on PCa cell line invasion in vivo.ResultsWe proved that high PrLZ expression initiates EMT, which was shown by the downregulation of E‐cadherin and upregulation of vimentin in PC‐3/PrLZ and ARCaP‐E/PrLZ cells. Mechanistic analysis revealed that PrLZ regulates EMT by activating TGF‐β1/p‐smad2 signaling and further inhibiting the expression of miR‐200 family members, which negatively regulates ZEB1 expression and causes EMT in Pca. Moreover, using two of orthotopic mouse model and tail vein injection of human prostate cancer cells mouse model, we observed that PC‐3/PrLZ cells led to the development of distant organ metastases in vivo.ConclusionsOur results show the mechanism by which PrLZ regulates EMT and metastasis and suggest that PrLZ may be a potential therapeutic target for Pca metastasis.

Publisher

Wiley

Subject

Urology,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3